Targeting BTN3A1 with the agonistic antibody CTX-2026 induced BTN3A1 switching from immunosuppressive to immunostimulatory conformations and promoted coordinated Vγ9Vδ2+ and CD8+ αβ T-cell anti-tumor responses against BTN3A1+ tumors (52). This evidence concerns the gene CD8A and neoplasm.